A controlled trial of methylene blue in severe depressive illness.
Methylene blue, 15 mg/day, was compared with placebo in treatment of severe depressive illness. The 3-week trial was designed to avoid bias by placebo response and also to avoid observer bias. Improvement in patients receiving methylene blue was significantly greater than in those receiving placebo. Methylene blue at a dose of 15 mg/day appears to be a potent antidepressant, and further clinical evaluation is essential.
D000328:Adult; D000368:Aged; D000928:Antidepressive Agents; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008751:Methylene Blue / Q000627:therapeutic use*; D008875:Middle Aged
D000928:Antidepressive Agents; D008751:Methylene Blue